Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients
出版年份 2016 全文链接
标题
Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients
作者
关键词
Immunotherapy, PD-L1, PD-1, Lung cancer, Immunohistochemistry, Diagnostic pitfalls
出版物
VIRCHOWS ARCHIV
Volume 468, Issue 5, Pages 511-525
出版商
Springer Nature
发表日期
2016-02-25
DOI
10.1007/s00428-016-1910-4
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- PD-L1 Testing in Cancer
- (2016) Aaron R. Hansen et al. JAMA Oncology
- PD-L1 Expression as a Predictive Biomarker
- (2016) Feriyl Bhaijee et al. JAMA Oncology
- Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non–Small-Cell Lung Cancer
- (2016) Joseph McLaughlin et al. JAMA Oncology
- Benefit-Risk Summary of Nivolumab for Patients With Metastatic Squamous Cell Lung Cancer After Platinum-Based Chemotherapy
- (2016) Dickran Kazandjian et al. JAMA Oncology
- European cancer mortality predictions for the year 2015: does lung cancer have the highest death rate in EU women?
- (2015) M. Malvezzi et al. ANNALS OF ONCOLOGY
- Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies
- (2015) M. Ilie et al. ANNALS OF ONCOLOGY
- Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
- (2015) Suzanne L. Topalian et al. CANCER CELL
- Addressing the unmet need in lung cancer: The potential of immuno-oncology
- (2015) G.V. Scagliotti et al. CANCER TREATMENT REVIEWS
- Immune Checkpoint Modulation for Non-Small Cell Lung Cancer
- (2015) J.-C. Soria et al. CLINICAL CANCER RESEARCH
- Cancer Immunotherapy: A Future Paradigm Shift in the Treatment of Non-Small Cell Lung Cancer
- (2015) V. K. Anagnostou et al. CLINICAL CANCER RESEARCH
- PD-1/PD-L1 inhibitors
- (2015) Joel Sunshine et al. CURRENT OPINION IN PHARMACOLOGY
- PD-L1 expression in small cell lung cancer
- (2015) Takefumi Komiya et al. EUROPEAN JOURNAL OF CANCER
- PD-L1 expression in small cell neuroendocrine carcinomas
- (2015) Anne M. Schultheis et al. EUROPEAN JOURNAL OF CANCER
- Companion diagnostic assays for PD-1/PD-L1 checkpoint inhibitors in NSCLC
- (2015) Jan Trøst Jørgensen EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
- Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future
- (2015) Lieping Chen et al. JOURNAL OF CLINICAL INVESTIGATION
- Programmed Death-Ligand 1 Immunohistochemistry in Lung Cancer: In what state is this art?
- (2015) Keith M. Kerr et al. Journal of Thoracic Oncology
- PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
- (2015) S. P. Patel et al. MOLECULAR CANCER THERAPEUTICS
- Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
- (2015) Christina Twyman-Saint Victor et al. NATURE
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
- (2015) Stephen M. Ansell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- PD-L1 Blockade for Cancer Treatment: MEDI4736
- (2015) Ramy Ibrahim et al. SEMINARS IN ONCOLOGY
- Adaptive Immune Resistance: How Cancer Protects from Immune Attack
- (2015) A. Ribas Cancer Discovery
- Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2014) M. Reck et al. ANNALS OF ONCOLOGY
- Programmed Cell Death 1 (PD-1) and Its Ligand (PD-L1) in Common Cancers and Their Correlation with Molecular Cancer Type
- (2014) Z. Gatalica et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- The Future of Cancer Therapy: Selecting Patients Likely to Respond to PD1/L1 Blockade
- (2014) A. Ribas et al. CLINICAL CANCER RESEARCH
- Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
- (2014) J. M. Taube et al. CLINICAL CANCER RESEARCH
- Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes
- (2014) Ching-Yao Yang et al. EUROPEAN JOURNAL OF CANCER
- Incorporating Immune-Checkpoint Inhibitors into Systemic Therapy of NSCLC
- (2014) Stéphane Champiat et al. Journal of Thoracic Oncology
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- L’accréditation selon la norme ISO 15189 d’un laboratoire de pathologie et de génétique somatique (LPCE, CHU de Nice) : retour d’expérience
- (2013) Kevin Washetine et al. ANNALES DE PATHOLOGIE
- A Mechanism of Hypoxia-Mediated Escape from Adaptive Immunity in Cancer Cells
- (2013) I. B. Barsoum et al. CANCER RESEARCH
- Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer
- (2013) M. Sznol et al. CLINICAL CANCER RESEARCH
- ALKin Lung Cancer: Past, Present, and Future
- (2013) Alice T. Shaw et al. JOURNAL OF CLINICAL ONCOLOGY
- Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours
- (2013) Jérôme Galon et al. JOURNAL OF PATHOLOGY
- Impact of EGFR Inhibitor in Non–Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis
- (2013) Chee Khoon Lee et al. JNCI-Journal of the National Cancer Institute
- Sarcomatoid Lung Carcinomas Show High Levels of Programmed Death Ligand-1 (PD-L1)
- (2013) Vamsidhar Velcheti et al. Journal of Thoracic Oncology
- The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment
- (2013) Paolo A Ascierto et al. Journal of Translational Medicine
- Programmed death ligand-1 expression in non-small cell lung cancer
- (2013) Vamsidhar Velcheti et al. LABORATORY INVESTIGATION
- Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells
- (2013) S. Spranger et al. Science Translational Medicine
- Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
- (2013) E. A. Akbay et al. Cancer Discovery
- Tumor B7-H1 and B7-H3 Expression in Squamous Cell Carcinoma of the Lung
- (2012) Jennifer M. Boland et al. Clinical Lung Cancer
- Pitfalls in Lung Cancer Molecular Pathology: How to Limit them in Routine Practice?
- (2012) M. Ilie et al. CURRENT MEDICINAL CHEMISTRY
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
- (2012) J. M. Taube et al. Science Translational Medicine
- Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
- (2011) R. D. Schreiber et al. SCIENCE
- Overall survival and PD-L1 expression in metastasized malignant melanoma
- (2010) Jules Gadiot et al. CANCER
- Quantitative Analysis of Tumor in Bronchial Biopsy Specimens
- (2010) Caroline L. Coghlin et al. Journal of Thoracic Oncology
- PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
- (2009) Loise M. Francisco et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)
- (2008) M. Marzec et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started